Evolutionary determinants of curability in cancer

Area of Science:

• Oncology
• Cancer Biology
• Evolutionary Medicine

Background:

• Drug resistance in adult cancers is a major obstacle to curative treatment, frequently associated with TP53 gene mutations.
• Conversely, rare TP53 wild-type malignancies exhibit high cure rates, suggesting TP53 status is critical in cancer curability.

Purpose of the Study:

• To explore the evolutionary and developmental factors underlying drug resistance by comparing common adult cancers with curable rare malignancies.
• To understand how TP53 gene function influences cancer cell evolution, drug resistance, and overall treatment outcomes.

Main Methods:

• Comparative analysis of genetic and phenotypic features of curable versus drug-resistant cancers.
• Review of the role of TP53 protein function in cancer cell survival, adaptation, and evolution under selective pressures.
• Examination of developmental origins of cancer cells and their impact on drug sensitivity.

Main Results:

• Acquired loss of TP53 protein function is a common event in cancer, conferring survival advantages and promoting evolvability.
• TP53-null cells exhibit resistance to apoptosis, tolerate DNA damage, and possess enhanced self-renewal capabilities, facilitating adaptation to therapies.
• Curable cancers, originating from embryonic/fetal cells, retain TP53-dependent apoptosis and drug hypersensitivity due to distinct developmental and genetic profiles.

Conclusions:

• TP53 loss is a key driver of drug resistance and poor prognosis in common adult cancers.
• The developmental origins and intrinsic genetic makeup of cancer cells significantly influence their susceptibility to therapies.
• Understanding these determinants could pave the way for novel therapeutic strategies targeting drug resistance mechanisms.